Keytruda

Imported from official source

Keytruda Active substance Pembrolizumab Holder MSD Belgium BV/SRL Status Running Indication in combination with paclitaxel with or without bevacizumab, is indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS ≥1 and who have received one or two prior treatment regimens. …

This version

Version
1 of 1
Recorded
November 17, 2026 09:31
Change
Initial
Content hash
1f605083e6b51c8409d725e09a97ee31
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.